Akari Therapeutics Plc financial data

Symbol
AKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, Fl 7, Boston, MA
State of incorporation
United Kingdom
Former names
Celsus Therapeutics Plc. (to 9/15/2015), Morria Biopharmaceuticals PLC (to 6/20/2013)
Latest financial report
10-Q - Q3 2024 - Nov 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 25.2 %
Return On Equity 648 %
Return On Assets -814 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.5B shares
Common Stock, Shares, Outstanding 24.3B shares
Entity Public Float 13.6M USD
Common Stock, Value, Issued 2.43M USD
Weighted Average Number of Shares Outstanding, Basic 24.4B shares +141%
Weighted Average Number of Shares Outstanding, Diluted 24.4B shares +141%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 2.37M USD
General and Administrative Expense 1.28M USD -44.2%
Operating Income (Loss) -13.6M USD -16.8%
Nonoperating Income (Expense) -1.95M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -23M USD -0.84%
Earnings Per Share, Basic -0.41 USD/shares
Earnings Per Share, Diluted -0.41 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.25M USD
Other Assets, Current 92K USD
Assets, Current 2.73M USD
Property, Plant and Equipment, Net 31.8K USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Intangible Assets, Net (Excluding Goodwill) 14K USD -17.6%
Other Assets, Noncurrent 11.1K USD
Assets 2.73M USD
Accounts Payable, Current 4.78M USD
Accrued Liabilities, Current 2.61M USD
Liabilities, Current 9.43M USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD
Liabilities 24M USD +359%
Accumulated Other Comprehensive Income (Loss), Net of Tax -926K USD
Retained Earnings (Accumulated Deficit) -243M USD
Stockholders' Equity Attributable to Parent -6.69M USD -3243%
Liabilities and Equity 2.73M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.04M USD +17.1%
Net Cash Provided by (Used in) Financing Activities 1.51M USD -52.9%
Common Stock, Shares Authorized 45.1B shares +28.9%
Common Stock, Shares, Issued 24.3B shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.54M USD -52%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.25M USD -52.5%
Deferred Tax Assets, Valuation Allowance 16M USD -44.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.19 pure
Deferred Tax Assets, Gross 16.1M USD -46.4%
Depreciation 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.4M USD -6.89%
Property, Plant and Equipment, Gross 753K USD -11.2%
Operating Lease, Liability, Current 4.6M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 43M USD +33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 19.9M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD +1200%
Deferred Tax Assets, Net of Valuation Allowance 16M USD -44.5%
Share-based Payment Arrangement, Expense 116K USD -18.7%
Interest Expense 51K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares